© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
April 29, 2021
A look toward the future development of bispecific T-cell engages (BiTEs) and CAR T-cell therapy for metastatic castration-resistant prostate cancer (mCRPC).
A review of the PSMA-targeted radioligand therapies that are currently in development.
April 20, 2021
Oliver Sartor, MD, reviews clinical data from the TheraP trial looking at the activity of 177Lu-PSMA617 in patients with metastatic castration-resistant prostate cancer.
Key opinion leaders expand on the broad clinical utility of prostate-specific membrane antigen (PSMA) for patients with advanced prostate cancer.